The Canadian life sciences sector is one of the fastest growing industries in Canada as it seeks to make innovative products to improve the lives of patients coast-to-coast.
One such company at the helm of the industry is Calgary, AB-based Voyageur Pharmaceuticals (TSXV:VM), a company focused on developing barium, iodine and carbon-active pharmaceutical imaging drugs. Notably, Voyageur Pharmaceutical is gearing up to produce its own barium, iodine and fullerene minerals.
In March, it revealed a partnership with Applied Pharmaceutical Innovation (API) that will undoubtedly transform Canada’s life sciences sector through the combined entities’ commitment to innovation.
Voyageur Pharmaceuticals and API collaborate
The company said in a press release that API will assist in accelerating Voyageur’s imaging contrast medium product development, manufacturing and commercialization.
Through API’s scientific and pharmaceutical experience, the collaboration will work towards notching regulatory approvals and getting Voyageur’s contrast imaging products to market in a timely fashion.
“This strategic alliance with API will accelerate Voyageur’s development programs, with a primary focus on creating a groundbreaking carbon-based MRI drug and advancing our iodine contrast media product pipeline,” Brent Willis, CEO of Voyageur Pharmaceuticals, said in a statement.
Notably, the partnership will target the US Food and Drug Administration, Health Canada and other regulatory agencies by licensing across key development areas such as:
- Accelerating the development of the V@C60 MRI drug
- Developing novel fullerene imaging products for targeted drug delivery in the body, focused on applications in diagnosing disease.
- Introducing an advanced suite of new barium contrast media products, to displace current available products
- Expanding the company’s lodine contrast media product pipeline, including the potential development of fullerene iodine products
In an interview with The Market Online, Willis said that the partnership with API will allow the company to accelerate its drug program, and develop the carbon and other products it is working on.
“The carbon C-60 molecule creates such a unique drug … because it creates an image that allows the doctors to distinguish between different tissues to identify the tumors and issues in the body by making it — in layman’s terms — brighter in order to see better imaging,” he explained.
Rain Cage Carbon and Voyageur collaboration
The company previously announced its licensing agreement with Rain Cage Carbon, a leader in carbon capture and reuse technology, to develop nanocarbon-based contrast drugs for medical imaging in May 2023.
As part of the collaboration, Voyageur Pharmaceuticals believes Rain Cage has achieved a significant technological breakthrough with the pioneering EDEN™ system, a technology capable of directly capturing CO2 and various other oxides from industrial emissions.
In line with this, Rain Cage Carbon revealed in March the launch of its approach to profitable decarbonization through Carbon Farms.
Carbon Farms is a multiple deployment of its proprietary Carbon Capture and Reuse technology, the EDEN™ System. The technology will transform CO2 emissions into a crystallized form of carbon known as Advanced Carbon and is suited for applications within the renewable power generation and energy storage markets.
“Our vision is to become the world’s first company capable of creating new carbon-based drugs from captured CO2, ensuring carbon-neutral pharmaceuticals,” Willis said in a statement.
The company believes producing carbon for Raincage will fund Voyageur’s development as the economics are too promising to ignore.
The investment corner
Carbon-based drugs from captured CO2 are undoubtedly set to be a game-changer in the life sciences industry, and Voyageur Pharmaceuticals is at the forefront of this innovation.
As the company marches towards product development, manufacturing and commercialization, investors will be keenly watching to see how it will transform the industry and beyond.
Join the discussion: Find out what everybody’s saying about this stock on the Voyageur Pharmaceuticals Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
This is sponsored content issued on behalf of Voyageur Pharmaceuticals, please see the full disclaimer here.